The January/February 2006 issue of
Contract Pharma
is available now!
Sponsored by Wellspring Pharmaceuticals
Looking for a contract service provider? Try our online Contract Services Directory
|
- Breaking News:
- Plus, don't miss out on the latest news in the Contract Pharma Industry at www.contractpharma.com/news.php
- Patheon Receives Frost & Sullivan Award
Frost & Sullivan has presented its 2005 Contract Manufacturing Company of the Year Award to Patheon for its concrete foundation and strategy for future growth as well as its exceptional customer service and superior market growth skills. Patheon has also developed innovative strategies to take advantage of market changes.... » Read More
Lilly Initiates Second Cancer Trial in Isis Collaboration
Eli Lilly and Co. has initiated clinical trials of LY2275796, an antisense drug that targets a protein involved in the growth and survival factors that contribute to tumor progression and the spread of cancers. LY2275796 was discovered in the Isis-Lilly drug discovery collaboration, and is the second antisense drug candidate from this strategic alliance to advance into Phase I development. Lilly will pay Isis Pharmaceuticals, Inc. $750,000 for the accomplishment of this milestone. Lilly is also funding the development of LY2275796 and will make additional payments on the achievements of certain development and regulatory milestones, and royalties on product sales to Isis.... » Read More
ImmunoGen Gets Genentech Milestone
Genentech's trastuzumab-DM1 IND submission to the FDA has triggered a $2 million milestone payment to ImmunoGen. Trastuzumab-DM1 comprises ImmunoGen's cell-killing agent, DM1, linked to Genentech's therapeutic antibody, trastuzumab, which targets overexpression of the HER2 protein.... » Read More
SGS Acquires aster.cephac
SGS has acquired aster.cephac, a full service provider of early clinical pharmacology trials and bioanalytical drug development services headquartered in Paris, France. With its 82-bed, newly refurbished state-of-the-art clinic, aster.cephac is one of the largest intensive care facilities in the world with access to a large volunteer base in Europe. Also, the company has recently invested in a modern and GMP-conforming pharmacy. Its facilities are in full compliance with the recent EU Directive.... » Read More
Codexis, BMS Extend Research Agreement
Codexis, Inc. has extended the term of an existing research agreement with Bristol-Myers Squibb and will receive an undisclosed milestone payment for having successfully achieved the program's research milestone.... » Read More
- Features:
- In this month's issue:
- Consolidation in Outsourcing
Our financial analyst sums up 2005's big moves
by Michael Martorelli
“The more things change, the more they remain the same.” So said the 19th century novelist and journalist Alphonse Kerr. That man would probably be astounded to see how many others have used that simple quote to explain profound occurrences across many aspects of business and of life. The nature of the consolidation that took place across the outsourcing industry in 2005 was different in many respects from that experienced in the preceding 12 months. Yet, while the names of the participants changed, their motives, perspectives, perceptions, and philosophies were very similar to those of the companies who found merger partners in 2004. Any way you measure i ... » Read entire article
- Process Documentation
Does it really have to be this difficult?
by Monique Garrett
Most sponsors, CROs and technology vendors in the life sciences industry have a good understanding of the risks associated with inferior process documentation. Minimally, failing an audit means lost time and money, a damaged relationship or reputation with the agency or a customer (or both) and diverted resources as the organization attempts to take corrective action or respond to an audit report. These outcomes are not worth the risk to most organizations. In our industry, you don’t get points for good intentions. If it isn’t documented, it didn’t happen. Therefore, a great deal of time and energy is spent on process documentation. The “burden” of ... » Read entire article
- Anti-Counterfeiting Initiatives and RFID Practices
Reward, Risk and Regulation
by Kristin Brooks
The year 2005 was a pivotal one for pharmaceutical companies as far as anti-counterfeiting initiatives and more specifically, radio-frequency identification (RFID). The World Health Organization (WHO) estimates that as much as 10% of the half-trillion-dollar pharmaceutical market is counterfeit and the FBI estimates the impact on U.S. companies is $200–$250 billion a year. The awareness and concern about counterfeit drugs in the pharmaceutical supply chain reached its peak in 2004. According to an FDA report, the number of drug counterfeiting cases had increased dramatically in 2004 (58 cases up from 30 in 2003). The increased attention on drug counterfeiting may have led to the ... » Read entire article
|
